Baidu
map

我国启动重大疑难疾病中西医临床协作试点:涉肝癌、糖尿病等

2018-03-25 田晓航 王宾 新华社

新华社北京3月24日消息,国家中医药管理局等三部门近日联合发出通知提出,自2018年1月起实施周期为3年的重大疑难疾病中西医临床协作试点工作,58个项目入选为试点项目,涉及糖尿病及并发症、肝癌、脑梗死等30余种疾病。通知说,试点工作以提高重大疑难疾病临床疗效为目的,中西医双方通过整合资源、优势互补、协同攻关,探索中西医结合防治疾病的新思路、新方法和新模式。随通知印发的《重大疑难疾病中西医临床协作

新华社北京3月24日消息,国家中医药管理局等三部门近日联合发出通知提出,自2018年1月起实施周期为3年的重大疑难疾病中西医临床协作试点工作,58个项目入选为试点项目,涉及糖尿病及并发症、肝癌、脑梗死等30余种疾病。

通知说,试点工作以提高重大疑难疾病临床疗效为目的,中西医双方通过整合资源、优势互补、协同攻关,探索中西医结合防治疾病的新思路、新方法和新模式。

随通知印发的《重大疑难疾病中西医临床协作试点项目实施办法》提出,在协作机制建立上,建立中西医人员紧密协作的会诊、联合门诊、联合查房、联合病例讨论、学术联合、高层次中西医人才交叉培养等协作模式及医疗制度,为患者提供从预防、治疗到康复一体化的中西医协作综合诊疗服务。

在协作重点内容上,上述办法提出,从临床入手,针对协作病种发生、发展过程中的某一阶段、关键环节,开展中西医协作联合攻关,挖掘整理中医药治疗经验和特色疗法,提炼临床经验,对诊疗方案的临床实施进行动态管理,强化对临床病例资料的分析、总结与评估,建立中西医结合疗效评价标准,形成独具特色的中西医结合诊疗方案或专家共识

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1641631, encodeId=d5821641631d3, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Mon Jul 30 18:19:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797325, encodeId=ef3b1e97325d8, content=<a href='/topic/show?id=d6ac22e322b' target=_blank style='color:#2F92EE;'>#临床协作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22732, encryptionId=d6ac22e322b, topicName=临床协作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 05 02:19:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463050, encodeId=03f31463050e3, content=<a href='/topic/show?id=83312253524' target=_blank style='color:#2F92EE;'>#中西医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22535, encryptionId=83312253524, topicName=中西医)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=693f6527574, createdName=lizhou0206, createdTime=Tue Mar 27 01:19:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1641631, encodeId=d5821641631d3, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Mon Jul 30 18:19:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797325, encodeId=ef3b1e97325d8, content=<a href='/topic/show?id=d6ac22e322b' target=_blank style='color:#2F92EE;'>#临床协作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22732, encryptionId=d6ac22e322b, topicName=临床协作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 05 02:19:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463050, encodeId=03f31463050e3, content=<a href='/topic/show?id=83312253524' target=_blank style='color:#2F92EE;'>#中西医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22535, encryptionId=83312253524, topicName=中西医)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=693f6527574, createdName=lizhou0206, createdTime=Tue Mar 27 01:19:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1641631, encodeId=d5821641631d3, content=<a href='/topic/show?id=c1bf91e4162' target=_blank style='color:#2F92EE;'>#试点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91741, encryptionId=c1bf91e4162, topicName=试点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a5522833467, createdName=ms1774076774505970, createdTime=Mon Jul 30 18:19:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797325, encodeId=ef3b1e97325d8, content=<a href='/topic/show?id=d6ac22e322b' target=_blank style='color:#2F92EE;'>#临床协作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22732, encryptionId=d6ac22e322b, topicName=临床协作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Feb 05 02:19:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463050, encodeId=03f31463050e3, content=<a href='/topic/show?id=83312253524' target=_blank style='color:#2F92EE;'>#中西医#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22535, encryptionId=83312253524, topicName=中西医)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=693f6527574, createdName=lizhou0206, createdTime=Tue Mar 27 01:19:00 CST 2018, time=2018-03-27, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map